Skip to main content
Erschienen in: Current Colorectal Cancer Reports 2/2013

01.06.2013 | Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria

verfasst von: Junichi Shindoh, Yun Shin Chun, Evelyne M. Loyer, Jean-Nicolas Vauthey

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Since the introduction of biological agents, accumulating results have suggested that conventional size-based RECIST criteria do not enable accurate assessment of response to therapy, and that non-size-based changes in tumor morphology can be a surrogate marker for assessment of chemotherapeutic effect. The morphological response criteria are recently introduced, non-size-based criteria for patients undergoing chemotherapy for colorectal liver metastases (CLM). These novel criteria predict pathologic response and long-term survival of patients treated with preoperative chemotherapy, with or without bevacizumab, irrespective of their RECIST response. They have been validated in patients with resectable and unresectable CLM. These criteria are difficult to apply for small metastases and can be used as an adjunct to RECIST in assessment of response to preoperative chemotherapy.
Literatur
1.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
2.
Zurück zum Zitat Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245–51.PubMedCrossRef Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245–51.PubMedCrossRef
3.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef
4.
Zurück zum Zitat Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357–65.PubMed Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357–65.PubMed
5.
Zurück zum Zitat Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619–28.PubMedCrossRef Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619–28.PubMedCrossRef
6.
Zurück zum Zitat Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012–20.PubMedCrossRef Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012–20.PubMedCrossRef
7.
Zurück zum Zitat Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;21:936–41.PubMedCrossRef Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;21:936–41.PubMedCrossRef
8.
Zurück zum Zitat Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef
9.
Zurück zum Zitat Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010;194:157–65.PubMedCrossRef Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010;194:157–65.PubMedCrossRef
10.
Zurück zum Zitat Smith AD, Shah SN, Rini BI, et al. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010;194:1470–8.PubMedCrossRef Smith AD, Shah SN, Rini BI, et al. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010;194:1470–8.PubMedCrossRef
11.
Zurück zum Zitat •• Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338–44. This paper and Ref. [18] first indicated the clinical relevance and predictive value of morphologic response criteria for patients undergoing chemotherapy for colorectal liver metastases. These studies showed that optimal morphologic response is associated with better survival, irrespective of the chemotherapy regimens or surgical treatment used.PubMedCrossRef •• Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338–44. This paper and Ref. [18] first indicated the clinical relevance and predictive value of morphologic response criteria for patients undergoing chemotherapy for colorectal liver metastases. These studies showed that optimal morphologic response is associated with better survival, irrespective of the chemotherapy regimens or surgical treatment used.PubMedCrossRef
12.
Zurück zum Zitat De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–15.PubMedCrossRef De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–15.PubMedCrossRef
13.
Zurück zum Zitat • Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23:948–54. This paper reported the limitation of the current version of RECIST in predicting patient outcomes after modern chemotherapy and also indicated the possibility of improving the diagnostic value of RECIST by modifying current cut-off values.PubMedCrossRef • Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23:948–54. This paper reported the limitation of the current version of RECIST in predicting patient outcomes after modern chemotherapy and also indicated the possibility of improving the diagnostic value of RECIST by modifying current cut-off values.PubMedCrossRef
14.
Zurück zum Zitat Glimelius B, Sorbye H, Balteskard L, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol. 2008;19:909–14.PubMedCrossRef Glimelius B, Sorbye H, Balteskard L, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol. 2008;19:909–14.PubMedCrossRef
15.
Zurück zum Zitat Blazer 3rd DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344–51.PubMedCrossRef Blazer 3rd DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344–51.PubMedCrossRef
16.
Zurück zum Zitat Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010;34:1287–94.PubMedCrossRef Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010;34:1287–94.PubMedCrossRef
17.
Zurück zum Zitat Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.PubMedCrossRef Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.PubMedCrossRef
18.
Zurück zum Zitat •• Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566–72. This paper and Ref. [11] first indicated the clinical relevance and predictive value of morphologic response criteria for patients undergoing chemotherapy for colorectal liver metastases. These studies showed that optimal morphologic response is associated with better survival, irrespective of the chemotherapy regimens or surgical treatment used. •• Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566–72. This paper and Ref. [11] first indicated the clinical relevance and predictive value of morphologic response criteria for patients undergoing chemotherapy for colorectal liver metastases. These studies showed that optimal morphologic response is associated with better survival, irrespective of the chemotherapy regimens or surgical treatment used.
Metadaten
Titel
Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria
verfasst von
Junichi Shindoh
Yun Shin Chun
Evelyne M. Loyer
Jean-Nicolas Vauthey
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 2/2013
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0164-7

Weitere Artikel der Ausgabe 2/2013

Current Colorectal Cancer Reports 2/2013 Zur Ausgabe

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

How Could the TNM System Be Best Adapted for Staging Rectal Cancer in the Future?

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Safety of Simultaneous Bowel and Liver Resections for Colon and Rectal Cancer

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.